Citations

Clear

696 citation(s) found for "Tyler, A".

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes
Garcia‐Manero, Guillermo , Saini, Lalit , Yacoub, Abdulraheem , Maness, Lori J., Foran, James M. , Lübbert, Michael , Lodewyck, Tom , Amin, Harshad, Bachiashvili, Kimo, Yimer, Habte, Zhu, Nancy , Lopez, Patricia Font, Priego, Victor, Odenike, Olatoyosi , Heyrman, Bert , Wan, Yubing, Chan, Winny, Oganesian, Aram , Sano, Yuri, Zeidan, Amer M. , Traer, Elie , Mohan, Sanjay , Xicoy, Blanca , Al‐Ali, Haifa Kathrin , Lopez, Patricia Font, Sanz, Guillermo , Santini, Valeria , Berdeja, Jesús G. , Valcárcel, David , Wan, Yubing, Keer, Harold N , Griffiths, Elizabeth A.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 790-790

10.1182/blood-2025-790 Get It

Abstract Background: Parenteral DNA methyltransferase inhibitors (DNMTi) such as azacitidine and decitabine (DEC), including an attenuated 3-day regimen, are recommended in the NCCN Guidelines for patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) with clinically significant cytopenias. However, parenteral administration requires frequent clinic visits, which imposes a substantial burden on pts, particularly those requiring long-term therapy. Oral DMTIs offer more flexible dosing and maintenance of pts' autonomy. Oral DEC-cedazuridine (DEC-C) is a fixed-dose combination tablet containing DEC (35 mg) and cedazuridine (100 mg). ASTX727-03 (NCT03502668) is a randomized, open-label, multicenter, phase 1/2 clinical trial evaluating safety, efficacy, and pharmacokinetics (PK) of various DEC-C doses and regimens in pts with LR-MDS. Phase 1 identified a 5-day regimen of DEC 10 mg/cedazuridine 100 mg as the optimized low-dose (LD) regimen. Phase 2 compares this LD regimen with the attenuated standard-dose (SD) regimen. Here, we report phase 2 results on efficacy, safety, PK, and pharmacodynamic (PD) data. Methods: Adults (aged ≥18 years) with International Prognostic Scoring System (IPSS) low-risk or Intermediate-1 MDS, ECOG PS 0−2, and ≥1 cytopenia or red blood cell (RBC) transfusion dependence were randomized 1:1 to receive oral DEC-C LD (10 mg x 5 days) or SD (35 mg x 3 days). The primary endpoint was hematologic response. Secondary endpoints included PK, PD (by LINE-1 demethylation), time to bone marrow blasts >5%, leukemia-free survival (LFS), overall survival (OS), and safety. Results: As of October 31, 2024, 81 pts were treated (LD arm: n=40; SD arm: n=41) and completed a median of 8.8 months on treatment. At cutoff, 17 (42.5%) and 12 (28.6%) LD and SD pts, respectively, were still continuing the study; 9 (22.5%) and 6 (14.6%) pts respectively, had discontinued treatment due to hematopoietic stem cell transplant. Median age was 70 (LD) and 75 (SD) years; 75.0% (LD) and 68.3% (SD) had IPSS Int-1 risk MDS and 60.0% vs 41.5% had IPSS-Molecular Lower-Risk MDS (very low, low, or moderate-low). Low-risk prognostic scoring system risk distribution was similar: Category 1 (2.5% vs 4.9%), Category 2 (47.5% vs 46.3%), and Category 3 (50.0% vs 48.8%). After a median follow-up of 29.3 months, median OS was 23.9 months (95% confidence interval [CI]: 13.0, not estimable [NE]) in the LD arm vs 26.0 months (95% CI: 19.4, 28.5) in the SD arm. Median LFS was 23.8 months (95% CI: 13.0, NE) and 25.7 months (95% CI: 17.8, 26.5), respectively. Hematologic improvement per International Working Group 2006 criteria was achieved in 27.5% (LD) and 26.8% (SD) of pts. Among RBC transfusion–dependent pts, 52.4% (LD) and 37.5% (SD) achieved ≥56-day independence and 47.6% (LD) and 20.8% (SD) achieved ≥112-day independence. Pts received a median of 10 (LD) and 9 (SD) cycles. Delayed cycles occurred in 72.5% (LD) vs 82.9% (SD) of pts; dose reductions occurred in 40.0% (LD) and 46.3% (SD) of pts. Both treatment regimens caused a decrease in blood counts, reaching a nadir before recovering in each cycle. Neutropenia was more pronounced during early cycles and was more severe in the SD arm. Blood counts across all lineages remained stable or improved through ≥12 cycles with the LD arm, suggesting a more favorable safety and tolerability profile. Grade ≥3 adverse events (AEs) occurred in 85.0% and 90.2% of pts in the LD and SD arms, respectively; treatment discontinuation due to AEs occurred in 2.5% and 17.1% of pts, respectively. Most commonly reported treatment-emergent AEs were anemia (42.5% LD, 39.0% SD), fatigue (32.5% LD, 43.9% SD), and thrombocytopenia (37.5% LD, 39.0% SD). Three deaths occurred in the trial: 2 in the LD arm, which were both unrelated to study treatment, and 1 in the SD arm (Pseudomonal bacteremia in Cycle 1), which was treatment related. Total AUC0–24 was 199 ng*h/mL in the LD arm and 465 ng*h/mL in the SD arm; AUC for all cycles of the LD arm was approximately half of the SD arm. Maximal % LINE-1 demethylation rate was lower with LD than SD, but narrowed by Cycle 3. Conclusion: LD oral DEC-C demonstrated comparable clinical benefit to SD oral DEC-C, with improved safety and tolerability, including fewer dose modifications and less severe myelosuppression. These findings support LD DEC-C as a potential optimal regimen for pts with LR-MDS. Clinical trial registration: NCT03502668
Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US
Ailawadhi, Sikander, Delea, Thomas, Humblet, Olivier, Inocencio, Timothy, Li, Mengying, Bryan, Alexandra, Moynahan, Aaron, Kroog, Glenn, Hampp, Christian, Little, Michelle, Ma, Qiufei, Ailawadhi, Sikander, Delea, Thomas, Humblet, Olivier, Inocencio, Timothy, Li, Mengying, Bryan, Alexandra, Moynahan, Aaron, Kroog, Glenn, Hampp, Christian, Little, Michelle, Ma, Qiufei

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3975-3975

10.1182/blood-2025-3975 Get It

Abstract Background: Four bispecific antibodies (bsAbs), teclistamab, elranatamab, talquetamab, and linvoseltamab have been approved for use in the U.S. in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). The objective of this analysis was to describe healthcare resources utilization (HCRU) in Medicare pts initiating treatment (≥1 medical claim) with teclistamab for R/R MM, and to explore how HCRU differs for pts who initiate in the inpatient (IP) vs outpatient (OP) setting. We focused only on teclistamab due to insufficient follow-up for robust analyses of other bsAbs. Methods: The study used data from a 100% sample of fee-for-service Medicare enrollment and medical (Parts A and B) claims data during the “study period” spanning from 12 months prior to the approval of teclistamab to the end of availability of claims data (Oct 25, 2021–Sep 30, 2024). The study population included all pts in the database with ≥1 diagnosis of MM and ≥1 claim for teclistamab ≥30 days prior to the end of the study period. Patients were required to be continuously enrolled for Medicare medical benefits for the 12 months up to and including the 1st claim for teclistamab (the “index date”). Other main eligibility criteria included: 1) index date on/after availability of both IP and OP procedure codes for teclistamab; 2) no claims for MM treatment other than teclistamab or a corticosteroid within 0–30 days post index date; 3) if 1st administration of teclistamab was in the OP setting, dosage was consistent with first step up dose (SUD) and 4) ≥65 years of age as of index date. For each patient, the follow-up period was defined as the period from the index date to first occurrence of death, end of continuous enrollment, or end of study period. Setting of initiation of treatment was defined based on the setting of the first claim for teclistamab (IP or OP). For pts who initiated teclistamab in the IP setting, completion of SUD was defined as ≥1 OP administration with a full treatment dose of teclistamab (i.e., not an SUD) that occurred ≥10 days post index date. For those who initiated teclistamab in an OP setting, completion of SUD was defined as ≥2 OP administrations of teclistamab at a full treatment dose. The number of hospitalizations and physicians' office and hospital OP visits during teclistamab treatment were calculated on a per patient per month (PPPM) basis. Results: A total of 2,185 pts had ≥1 claim for teclistamab during the study period. Of these, 1,373 met all eligibility criteria. Mean (median) age at index date was 75 (74) years and 49% were female. Mean (median [range]) follow-up was 8.2 (7 [0.2–22.7]) months. Overall, 87% of pts initiated teclistamab in an IP setting, with a mean length of stay (LOS) for the index hospitalization of 9.3 days. Among those initiating teclistamab in an OP setting, 41% were hospitalized within 1 month of treatment initiation. Among all pts (IP or OP initiation of treatment), the Kaplan–Meier estimated median duration of teclistamab treatment was 6.1 months; 87% of pts completed SUD. Patients had a mean (median) of 0.72 (0.32) hospitalizations PPPM and 6.4 (5.8) hospital outpatient or physician's office visits PPPM during teclistamab treatment. Conclusions:Most pts with MM receiving teclistamab initiate treatment in an IP setting, with hospital LOS consistent with dosing guidance from the prescribing information. A substantial proportion of those who initiate teclistamab in an OP setting are hospitalized within 30 days. Treatment duration and percentage of pts completing SUD were consistent with values in other real-world studies of teclistamab. Patients receiving teclistamab have a high hospitalization burden during treatment initiation and frequent hospitalizations and OP visits over the course of treatment. These results highlight the need for novel treatments, administration models, and/or implementation of standardized supportive care guidelines to reduce the hospital burden and increase time on treatment for pts receiving bsAbs in real world settings.
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
Meyerhardt, Jeffrey A. , Twombly, Tyler S., Pederson, Levi , Väyrynen, Juha P. , Zhao, Melissa , Shergill, Ardaman , Kumar, Pankaj , Couture, Felix, Kuebler, Philip , Krishnamurthi, Smitha , Giannakis, Marios , Ogino, Shuji, Sharma, Shruti, Aleshin, Alexey , Shields, Anthony F. , Kuebler, J. Philip , Meyerhardt, Jeffrey A , Väyrynen, Juha , Zhang, George Q. , Shi, Qian , Ma, Chao , Takashima, Yasutoshi , Couture, Felix, Tan, Benjamin, O’Reilly, Eileen M. , Ogino, Shuji , Jurdi, Adham Adel , Sharma, Shruti , Nowak, Jonathan A.

Mayo Clinic

JAMA Oncology | December 4, 2025 | Volume: 12 | Issue: 2 | Pages: 149

10.1001/jamaoncol.2025.5144 | PMID 41343176 Get It

Importance Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer. While randomized clinical trials have not shown benefit across all patients, these findings suggest that select subgroups may benefit from their use. Despite the well-established prognostic value of circulating tumor DNA (ctDNA), its role in guiding treatment remains unclear. Objective To investigate the predictive value of postoperative ctDNA for survival outcomes with adjuvant celecoxib alongside conventional chemotherapy in patients with stage III colon cancer. Design, Setting, and Participants This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer. Patients consented to biospecimen collection and had ctDNA analysis performed. Data analysis was performed from September 2024 to June 2025. Exposures Postoperative ctDNA positivity was determined using a clinically validated, tumor-informed 16-plex-polymerase chain reaction-next-generation sequencing assay (Signatera; Natera Inc) performed between surgery and initiation of adjuvant therapy. Main Outcomes and Measures Disease-free survival (DFS) and overall survival (OS). Survival by ctDNA status and adjuvant celecoxib use were assessed as part of a post hoc companion study with prespecified statistical analysis plan. Results Among 940 patients (mean [SD] age, 60.9 [10.8] years; 426 female [45.3%] and 515 male [54.7%] individuals; 222 [23.6%] with prior low-dose aspirin use; and median follow-up of 6.0 [95% CI, 6.0-6.0] years), 767 (81.6%) were ctDNA negative and 173 (18.4%) were ctDNA positive. ctDNA positivity was highly prognostic of worse DFS (reference, ctDNA negativity; adjusted hazard ratio [aHR], 6.12; 95% CI, 4.66-8.03) and OS (aHR, 5.86; 95% CI, 4.19-8.19). In patients with ctDNA positivity, celecoxib was associated with improved DFS (aHR, 0.61; 95% CI, 0.42-0.89) and OS (aHR, 0.62; 95% CI, 0.40-0.96) compared to placebo. Among patients with ctDNA negativity, celecoxib did not provide survival benefit (DFS: aHR, 0.76; 95% CI, 0.53-1.09; OS: aHR, 0.85; 95% CI, 0.54-1.36), although the interaction was not significant ( P for interaction, .41 and .33 for DFS and OS, respectively). These findings persisted when stratifying patients by microsatellite instability status and PIK3CA mutational status. Conclusion and Relevance The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. Trial Registration ClinicalTrials.gov Identifier: NCT01150045
Multi-modality Artificial Intelligence for Involved-Site Radiation Therapy: Clinical Target Volume Delineation in High-Risk Pediatric Hodgkin Lymphoma
Milgrom, Sarah A. , Charpentier, AM, LaRiviere, M.J., Kelly, Kara M. , Hodgson, Darren , Castellino, S, Tie, Xin , Hodgson, David C. , Cho, S Y, Hodgson, D, Castellino, Sharon M. , Hoppe, Bradford S. , Bradshaw, Tyler

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812957 Get It

Prognostic value of 18F-FDG PET/CT volumetric parameters in childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL): a systematic review from the international SEARCH group (Staging, Evaluation and Response Criteria Harmonization)
Castellino, S, Dieckmann, Karin, Kelly, Kara M. , Kurch, Lars , Lai, Hollie , Mauz-Koerholz, Christine, McCarten, Kathleen M. , Steglich, J., Stoevesandt, Dietrich, Voss, Stephan D. , Milgrom, Sarah A. , Gowdy, Claire , Flerlage, Jamie E. , Seelisch, Jennifer , Palese, M, Bradshaw, Tyler , Castellino, Sharon M. , Cho, Steve K. , Hoppe, Bradford S. , Howard, Scott C. , Lopci, Egesta , Lucas, John T. , Mauz‐Körholz, Christine , Pandit-Taskar, Neeta D. , Schöder, Heiko

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812922 Get It

Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study
Pope, Jill , Smith, Gregory L. , Goree, Johnathan , Mekhail, Nagy , Levy, Robert M. , Deer, Timothy R. , Vu, Chau , Shah, Jarna R , Costandi, Shrif , Rosen, Steven M., Bromberg, Todd A., Patel, Atish, Latif, Usman , Lad, Shivanand P. , Jameson, Jessica , Calodney, Aaron , Falowski, Steven , Smith, J. Carson , Guirguis, Maged , Boeding, Ronald B., Sprintz, Michael, Antony, Ajay, Patterson, Denis G., Laufer, Andras, Pilitsis, Julie G. , Miller, Nathan , Rosenfeld, David J. , Tate, Jordan L, Raslan, Ahmed M. , Kallewaard, Jan Willem , Leitner, Angela , Hanson, Erin, Soliday, Nicole, Petersen, Erika , Goree, Johnathan A , Mekhail, Nagy A , Costandi, Shrif J , Lam, Christopher M , Hayek, Salim , Hagedorn, Jonathan M , Kallewaard, Jan Willem , Duarte, Rui , Deer, Tim , Shah, Jarna , Rosen, Steven M, Sayed, Dawood , Lam, Christopher , Hayek, Salim M. , Hagedorn, Jonathan M. , Heros, Robert , Miller, Nathan, Tate, Jordan L, Hanson, Erin, Duarte, Rui

Mayo Clinic

Regional Anesthesia & Pain Medicine | December 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107051

10.1136/rapm-2025-107051 | PMID 41330601 Get It

Background The efficacy of EVOKE therapy, a closed-loop spinal cord stimulation (SCS) system, has been demonstrated in a double-blinded randomized controlled trial (RCT). RCT evidence, however, may not be generalizable to clinical practice, while limitations of real-world evidence may affect its validity. The aim of this study was to evaluate the effectiveness of EVOKE therapy in routine clinical practice employing a rigorous data collection approach. Methods The ECAP study was a prospective, multicenter, single-arm, pragmatic study that enrolled SCS candidates with chronic, intractable trunk and/or limb pain in 22 US investigational sites. PROMIS-29 questionnaire and objective neurophysiological metrics were collected, and minimal clinically important differences (MCIDs) were used to characterize baseline dysfunction and response to EVOKE therapy both at trial end and maximal analgesic effect post-implant visit. Pre-specified subgroup analyses were conducted based on diagnosis. Results EVOKE therapy observed included a dose ratio of 1.3 and neural dose accuracy of 2.8 μV. Improvements of >1 MCID were observed for all domains and improvements of ≥2 MCIDs were observed for six of the seven domains. Improvements observed at trial end were maintained or improved at post-implant visit, with statistically significant improvement in holistic MCID (MD 0.2, 95% CI 0.1 to 0.4, p=0.004), and a significantly greater proportion of patients considered holistic MCID responders (p=0.047). Subgroup analysis by diagnosis showed similar outcomes. Conclusions EVOKE therapy was associated with clinically meaningful improvements in a real-world chronic pain population across different subgroups and disease pathologies, with effects observed at trial end reproduced at post-implant visit.
Admission Acid-Base Status and Mortality in Cardiac Intensive Care Unit Patients
Canova, Tyler J., Lipps, Kirsten , Hillerson, Dustin , Jentzer, Jacob C. , Canova, Tyler , Dahiya, Garima , Hillerson, Dustin B, Jentzer, Jacob C , Hillerson, Dustin , Kashani, Kianoush

Mayo Clinic

Journal of Intensive Care Medicine | November 28, 2025 | Volume: 41 | Issue: 7 | Pages: 670-682

10.1177/08850666251399182 | PMID 41313337 Get It

Background There is limited evidence on the epidemiology and prognostic significance of acid-base disorders in the cardiovascular intensive care unit (CICU). This study examines the association of acid-base status at admission with in-hospital mortality among CICU patients. Methods We conducted a retrospective analysis of adults admitted to the Mayo Clinic CICU from 2007-2018 with available blood gas data, utilizing values obtained closest to CICU admission. Arterial pH, serum bicarbonate, base excess, and partial pressure of carbon dioxide (PaCO 2 ) were examined as predictors of in-hospital mortality. Multivariable logistic regression was used to assess associations, with adjustment for demographics, comorbidities, illness severity, and interventions. Results Among 3229 patients included for analysis, acidemia (pH < 7.35) emerged as the strongest predictor of in-hospital mortality (adjusted odds ratio [aOR] 1.60, 95% confidence interval [CI] 1.29-1.98, P < .003). Metabolic acidosis (HCO3 < 20 mEq/L, aOR 1.55, 95% CI 1.24-1.95, P < .001) and respiratory acidosis (PaCO2 > 45 mm Hg, aOR 1.44, 95% CI 1.14-1.81, P = .002) were associated with higher in-hospital mortality, whereas metabolic and respiratory alkalosis were not. After adjustment, lower pH and more negative base excess were associated with higher in-hospital mortality (both P < .001), whereas HCO3 and PaCO2 were not ( P = .053 and P = .051, respectively). Patients with combined metabolic and respiratory acidosis had the highest in-hospital mortality (56.3%). Conclusions Short-term survival in CICU patients decreases progressively with worse acidemia, especially in the context of combined metabolic and respiratory acidosis. Incorporating metabolic acid-base disorders as key therapeutic targets in randomized cardiogenic shock trials may improve outcomes in this complex population by addressing hemometabolic shock.
Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough
Kim, Ian , Vukkadala, Neelaysh , Barbu, Anca M. , Razura, Diego E. , Gallagher, Tyler J. , Li, Albert

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | November 26, 2025 | Volume: 152 | Issue: 2 | Pages: 163

10.1001/jamaoto.2025.4181 | PMID 41296333 Get It

Importance Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become substantially more popular as a medication to treat obesity and type 2 diabetes (T2D). Despite their known association with gastroesophageal reflux disease and vagal nerve stimulation, the association between GLP-1RAs and chronic cough has not been previously studied. Objective To assess the clinical association between GLP-1RAs and chronic cough. Design, Setting, and Participants This large, multicenter cohort study used clinical records from a US-based collection of electronic medical record data from April 28, 2005, to April 15, 2025, from 70 health care organizations. Adults (≥18 years) with T2D and prescription of a GLP-1RA were identified. Additionally, groups with T2D and prescription of another second-line diabetes medication, including dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and sulfonylureas were created. After propensity score matching for various demographic and clinical characteristics, adjusted hazard ratios (aHRs) and 95% CIs were calculated using Cox regression analyses to estimate the risk of new chronic cough or gastroesophageal reflux disease diagnosis. Exposure GLP-1RAs or other second-line diabetes medication. Main Outcomes and Measures Chronic cough. Results Cohorts included 427 555 individuals (mean [SD] age, 55.8 [13.8] years; 251 928 female individuals [58.9%]) with T2D who were prescribed a GLP-1RA and 1 614 495 individuals (mean [SD] age, 63.7 [13.3] years; 712 946 female individuals [44.4%]) with T2D who were prescribed another second-line diabetes medication. After propensity score matching, individuals prescribed a GLP-1RA had significantly increased risk of new chronic cough compared with individuals prescribed any non–GLP-1RA second-line medication (aHR, 1.12; 95% CI, 1.08-1.16), DPP-4 inhibitor (aHR, 1.18; 95% CI, 1.11-1.26), or sulfonylurea (aHR, 1.32; 95% CI, 1.24-1.40) but not compared with SLGT2 inhibitors (aHR, 1.03; 95% CI, 0.98-1.09). After removing patients with a previous diagnosis of gastroesophageal reflux disease from analysis, patients prescribed GLP-1RAs had significantly increased risk of chronic cough compared with those prescribed any non–GLP-1RA (aHR, 1.29; 95% CI, 1.17-1.42), DPP4 inhibitor (aHR, 1.36; 95% CI, 1.17-1.58), SGLT2 inhibitor (aHR, 1.14; 95% CI, 1.02-1.28), or sulfonylurea (aHR, 1.25; 95% CI, 1.09-1.42). Conclusions and Relevance This cohort study suggests an association between GLP-1RA use and chronic cough. Further research is needed to confirm the existence, strength, and mechanisms of this association.
Temporal Elements of Speech in Mania
Joyce, Jeremiah B. , Joyce, Jeremiah , Ayala, Ivan N. , Chatzisofroniou, George, Clemens, Erik , Yu, Hang , Kendall, Tyler S. , Attia, Zachi, Lin, Baihan , Frye, Mark A.

Mayo Clinic

No container title available | November 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7613536/v1 Get It

Abstract Computational analysis of speech enables precise, objective measurements of a behavioral signal closely linked to manic episodes. In a prospective cohort study conducted in Rochester, MN ( ClinicalTrials.gov Identifier: NCT05956340 ) , eighteen English-speaking adults voluntarily hospitalized for a manic episode of Bipolar I Disorder between August 2023 and September 2024 were enrolled. Participants completed semi-structured research interviews during both acute episodes and remission, with manic symptom severity assessed at each session using the Young Mania Rating Scale (YMRS). Across 57 recorded interviews, temporal prosodic features were extracted using automated computational algorithms. After adjusting for individual differences and moderating effects, participant articulation rate (β = 0.24, p = 0.0038), speech rate variability (β = 0.23, p = 0.0041), floor transfer offset (β = -0.31, p = 0.007), and speaking duration (β = 0.54, p < 0.001) were significantly associated with manic symptom severity. These temporal elements classified manic (CV AUC = 0.85) and remission (CV AUC = 0.83) status, highlighting their potential as monitoring and prognostic biomarkers for manic episodes.
Care coordination in screening, brief intervention, and referral to treatment (SBIRT): A scoping review
Hadani, Yael, Tarikogullari, Idil , Oesterle, Tyler , McGinnis, Michele , Nidey, Nichole , Kalata, Alyssa H. , Bormann, Nicholas L. , Oesterle, Tyler S , Lai, Benjamin , Kalata, Alyssa H , Bormann, Nicholas L , McGinnis, Michele T , Lai, Benjamin , Sharma, Pravesh

Mayo Clinic

The American Journal on Addictions | November 23, 2025 | Volume: 35 | Issue: 1 | Pages: 22-35

10.1111/ajad.70104 | PMID 41275369 Get It

Abstract Background and Objectives Implementation of screening, brief intervention, and referral to treatment (SBIRT) for substance use in primary care remains challenging. Care coordination (CC) may strengthen SBIRT by supporting brief interventions, improving referral follow‐through, and enhancing continuity. CC models and outcomes vary, however, and no prior scoping review has synthesized these. Methods A comprehensive search of 10 resources, including Embase, MEDLINE, and PsycINFO, was conducted on 4/15/2025. Eligible studies described outpatient SBIRT models adding CC for any age group. Articles were excluded if they lacked CC, presented no original data, or were not in English. Relevant implementation and patient‐level outcomes were extracted to describe CC models and their impact. Results Of 737 abstracts and 50 full texts reviewed, 15 met the inclusion criteria. Studies spanned primary care, specialty care, and age ranges. CC models included embedded behavioral health providers, centralized linkage managers, and remote coordinators using phone or digital platforms. CC was associated with higher screening completion, brief intervention delivery, referral initiation, and treatment engagement. Successful integration incorporated structured communication, follow‐up protocols, and accessible technology. Barriers included limited billing infrastructure, weak electronic record integration, and unclear roles. Discussion and Conclusions CC appears to enhance SBIRT implementation and treatment engagement across outpatient settings. Embedded approaches offer relational benefits, while remote and digital strategies show promise for scalability. Comparative studies are needed to assess effectiveness, cost, and contextual fit. Scientific Significance Provides the first review of CC models within SBIRT, highlighting their implementation impact and guiding future optimization.